All In Biotech

Drug Trial Radar · NCT03945812

Platelet-Rich Plasma vs. Granulocyte Colony-Stimulating Factor vs. Placebo and Outcomes in Frozen Embryo Transfer

The Impact of Using Platelet-Rich Plasma Versus Granulocyte Colony-Stimulating Factor Versus Placebo on the Outcomes of Frozen Embryo Transfer: A Double Blind Randomized Controlled Trial

Last checked: Nov 19, 2026Latest source record: Aug 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 665 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

665

Actual

Start

Jun 1, 2019

Primary completion

Mar 31, 2022

Study completion Mar 8, 2023

Sponsor

Lead sponsor
Wael Elbanna ClinicAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Research Centre, Egypt
First posted
May 10, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 20 years, up to 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to assess the impact of using Platelet-Rich Plasma (PRP) vs. Granulocyte Colony-Stimulating Factor (GCSF) vs. placebo on the outcomes of frozen embryo transfer (FET) in terms of clinical pregnancy rates. It will also assess their effect on chemical pregnancy rate, implantation rate, delivery outcomes, and endometrial parameters. The main questions it aims to answer are: Do the clinical pregnancy rates differ upon using PRP vs. GCSF vs. placebo during FET? What are the effects of PRP vs. GCSF vs. placebo during FET on chemical pregnancy rate, implantation rate, delivery outcomes, and endometrial parameters? Researchers will compare the effect of administration of PRP vs. GCSF vs. placebo during FET on pregnancy outcomes. Participants will be randomized to receive the study intervention seven days before embryo transfer: 1.0 ml of either PRP (prepared in-house), GCSF (Filgrastim, 300 mcg/1.0 mL), or 0.9% saline (placebo). The intervention will be administered by slow infusion into the uterine cavity with an intrauterine insemination catheter.

Conditions

  • Infertility
  • Frozen Embryo Transfer (FET)

Interventions

  • Granulocyte Colony Stimulating FactorDrug

    Filgrastim, Amgen, California, USA 300 mg/1.0 mL

  • Platelet Rich Plasma ArmOther

    Platelet Rich Plasma Arm

  • SalineOther

    Saline 9%

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The clinical pregnancy rateTime frame: 6 to 8 weeks of embryo transfer

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hayat center

    Maadi, Cairo Governorate, Egypt

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.